Researchers approach a universal cancer vaccine

Wild pixels | IStock | Getty pictures

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

A universal cancer vaccine – what once seemed like a pipe dream – could approach reality.

On Friday, researchers from the University of Florida said that results from a new study could lead to the development of a universal shot that can start the immune system to combat cancer. The study of mice published in Nature Biomedical Engineering showed that an experimental MRNA vaccine increased the tumor control effects of a common cancer medication called Immun-Checkpoint inhibitors.

The vaccine is not designed for a certain virus or cancer cells, but to “wake up” the immune system against the disease “to react as if you are fighting a virus,” said a UF release.

“We found that a vaccine is used not to specifically target cancer, but to stimulate a strong immunological reaction, we were able to create a very strong reaction against cancer reaction,” said Dr. Duane Mitchell, co-author of the study and professor of neurosurgery at the medical college of Medicine at the university.

This is different from current approaches to cancer vaccines in which a goal is found that is expressed by many cancer patients or in the event of a case of Modern And MerchantDevelopment of personalized vaccines that are tailored to the specific tumor of each patient.

The universal vaccine has the potential to be used largely in cancer patients, “even a cancer-suffering cancer vaccine,” said Mitchell.

The UF researchers are still working on replicating the results in humans. If this is the case, a vaccine with a sizes could offer an alternative to operations, radiation and chemotherapy.

This is how the vaccine works: The MRNA shot essentially calls on the body to produce certain proteins that stimulate the immune system, including one that is called PD-L1 and can often be found on the surface or within cancer cells. These cells often use PD-L1 to hide from immune attacks.

By increasing PD-L1, however, the vaccine tumors can make more susceptible to immune checkpoint inhibitors that block this protein more susceptible and contribute to recognizing and destroying the immune system.

The study showed promising results on treatment-resistant tumors in skin cancer by combining the mrNA vaccine with a monoclonal antibody, a frequent immunotherapy medication that tries to draw the immune system aware that a tumor is foreign and attacked.

It also showed positive results when they were tested as a solo treatment of cancer of mouse, bones and brain test. In some cases, the tumors were completely eliminated.

“This paper describes a very unexpected and exciting observation: even a vaccine that is not specifically for a certain tumor or virus it is a mRNA vaccine-could lead to tumor-specific effects,” said the high-ranking author Dr. Elias Sayour, a pediatric oncologist from UF, in a release.

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

Latest in the healthcare system Tech: Digital Health Earning season is approaching.

We are only removed from the highlight of the digital health earnings season for a few days, and this quarter will certainly be interesting.

The two companies, the beginning of this year, went to the stock exchange, will report results for the first time since their debut. And since President Donald Trump's tax and expenditure law adopts and approaches his tariff period on August 1st, we will get an insight into the operation of digital health companies against a volatile macroeconomic and political backdrop.

Here are some of the reports on which CNBC will be observed:

Health hinge – August 5th

• The digital physiotherapy company HEALTH will publish its result in the second quarter on August 5, its first report since its debut at the New York Stock Exchange in May. The stocks of Hinge were opened on May 229.25 and they act on Wednesday after trading with Intraday over $ 46. In his first quarter of this year this year rose by 50% to $ 123.8 million, compared to $ 82.7 million in the previous year, and this net income for the period was $ 17.1 million compared to a loss of $ 26.5 million before the previous year.

Omada Health – August 7th

• The Virtual Chronic Care Company, Omada Health, will report results in the second quarter on August 7, which reveals finance data for the first time since his debut in June. The stocks of Omada were opened on June 6th at 23 USD and they act on Wednesday for trade in trade with around 19 US dollars. According to the prospectus, Omada's turnover rose by 57% in the first quarter to $ 55 million compared to $ 35.1 million in the previous year.

Hims & Hers Health – August 4th

• Telemealth Company HIMS & HERS Health Reports Reports in the second quarter on August 4th and managers will probably have questions about his short -lived cooperation with jobs Novo Nordisk. In April, Novo Nordisk said that Wegovy would offer several telemedicine companies, including HIMS & Her, to expand access to the injection of the blockbuster weight loss. But at the end of June, the deal collapsed over the sale and promotion of cheaper qualifications from HIMS & Huls. The shares of HIMS & HIS rose by more than 100% after the intraday trade on Wednesday after the intraday trade.

Doximity – August 7th

• Doximity, a digital platform for medical professionals, was one of the few breakout stars from 2024 when the company's share price more than doubled. Investors will observe closely whether the company can maintain its dynamics if the results report on August 7 in the first quarter of 2026. The stocks of doximity rose by more than 13% this year after the intraday trade on Wednesday.

Teladoc Health – July 29th

• The CEO of Teladoc Health, Chuck Divita, has worked after four right quarters with sales declines and an extended slump in stock burglary to turn the once high -flying company in a row. The company will publish results in the second quarter on July 29. The TELADOC shares decreased by more than 4% by the time of Intraday trading on Wednesday.

We will have a lot to dive in the coming weeks. So keep the reporting of CNBC step.

Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.